Clinical Trials

Contact Us

Leukemia, MDS


A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease

S1612 (NCT03092674)

A Randomized Phase II/III Trial of Novel Therapeutics versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), age 60 or Older (LEAP: Intergroup Less Intense AML Platform Trial)

Connect® MDS/AML Disease Registry (NCT01688011) – ONLY AVAILABLE AT MBMC

Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry